Biomea Fusion Reports New Preclinical Data on Icovamenib-Semaglutide Combination Study

New in vivo preclinical data announced today, demonstrate that icovamenib, in combination with semaglutide showed additional 11.5% body weight reduction and 43% increase in lean muscle mass compared to semaglutide aloneIcovamenib, in combination with semaglutide, approximately doubled C-peptide production per unit of glucose compared to semaglutide alone leading to a 60% improved reduction of fasting blood glucoseEx vivo human islet experiments previously presented in October, showed that icovamenib enhance ...